LASAACI 2021 Fall Symposia

September 11, 2021 to September 13, 2021

It is an exciting time in the field of allergy and immunology!  This CME program is designed to allow attendees to continue exploring the Immunology Frontier.  Covered topics include current and emerging treatments in atopic dermatitis, oral immunotherapy and asthma management.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Los Angeles Society of Allergy, Asthma & Clinical Immunology, Inc. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Commercial Support
This activity is supported in part by medical education grants from Astra Zeneca and Genentech.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1.    Describe potential benefits and risks of JAK inhibitors in atopic dermatitis
  2.   Identify the key features for safe and successful implementation of OIT in the office-based setting 
  3.   Recognize the pathophysiology of airway epithelial inflammation
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
Course expires: 
Event starts: 
09/11/2021 - 8:30am CDT
Event ends: 
09/13/2021 - 1:30pm CDT

Mark Boguniewicz, MD – Speaker
Consultant: AbbVie, 
Advisory Board Member: Eli Lily, Pfizer, Regeneron, Sanofi, Janssen, LEO Pharma
Research Grant: Regeneron, Incyte

Warner Carr, MD – Speaker
Consultant: AstraZeneca, Teva, Merz
Speaker: AstraZeneca, DBV Technologies, Merz

Matthew Greenhawt, MD, MBA, MSc – Speaker
Advisory Board Member: DBV Technologies, Sanofi/Regeneron, Nutricia,Novartis, Aquestive, Allergenis, Prota, Pfizer,ALK-Abello 
Associate Editor: ACAAI
Speaker: MedLearning Group, ImSci, ConnecticutChildren’s Medical Center 
Consultant: Aquestive, Allergenis 
Scientific Advisory Board: National Peanut Board 
Member: Joint Taskforce on Practice Parameters 

Travis A. Miller, MD – Speaker
Independent Contractor: DBV Technologies
Speaker: Genentech, Optinose

Raffi Tachdjian, MD – Planner
Speaker: Sanofi Regeneron, GSK, Takeda, CSL Behring, Pharming, Biocryst
Advisory Board Member: Sanofi Regeneron, Takeda, CSL Behring, Pharming, Biocryst, Allakos, Ionis

Sonal Patel, MD – Planner
Speaker: Sanofi Regeneron

Rita Kachru, MD – Planner
Independent Contractor : Aimmune, Genentech
Jonathan Corren, MD – Planner
Speaker: AstraZeneca, Genentech, Novartis, Regeneron, Sanofi
Independent Contractor: AstraZeneca, Genentech, Novartis, Optinose, Regeneron, Sanofi, Teva
Consultant: AstraZeneca, Novartis, Regeneron, Sanofi
Advisory Board Member: AstraZeneca, Novartis, Optinose, Regeneron, Sanofi

The following have no relevant financial relationships to disclose:
Danica Schulte, MD – Planner, Moderator
Sheila M. Bonilla, MD – Planner
Dean Chiang, MD – Planner
Edward Hu, MD – Planner
Caroline Spagnola, MD – Planner
Andrew K. Wong, MD – Planner
Joseph Yusin, MD – Planner
Karol Anderson – Planner

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.